PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35535581-3	2022	Minnelide , an oral anti-super-enhancer drug that inhibits MYC expression in preclinical models of ASCP, has demonstrated safety in a Phase I study.	14-O-phosphonooxymethyltriptolide disodium salt	0-9	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	59-62	
23499892-5	2013	Triptolide/Minnelide effectively downregulated the levels of pro-survival proteins such as heat shock proteins, cMYC, survivin and targets the NF-kappaB pathway.	14-O-phosphonooxymethyltriptolide disodium salt	11-20	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	112-116